Abstract
Metabolic syndrome (MetS) is a leading public health and clinical challenge worldwide. MetS represents a group of interrelated risk factors that predict cardiovascular diseases (CVD) and diabetes mellitus (DM). Its prevalence ranges between 10 and 84%, depending on the geographic region, urban or rural environment, individual demographic characteristics of the population studied (sex, age, racial and ethnic origin), as well as the criteria used to define MetS. Persons with MetS have higher mortality rate when compared with people without MetS, primarily caused by progressive atherosclerosis, accelerated by pro-inflammatory and pro-coagulation components of MetS. Considering the high prevalence of metabolic disorders (glucose metabolism disorder, hypertension, dyslipidaemia, obesity etc.), preventive healthcare should focus on changing lifestyle in order to reduce obesity and increase physical activity. This narrative review considers the available evidence from clinical and experimental studies dealing with MetS, and current treatment options for patients with insulin resistance and MetS.
Keywords: Metabolic syndrome, insulin resistance, cardiovascular disease.
Graphical Abstract
Current Vascular Pharmacology
Title:Link between Metabolic Syndrome and Insulin Resistance
Volume: 15 Issue: 1
Author(s): Zoran Gluvic, Bozidarka Zaric, Ivana Resanovic, Milan Obradovic, Aleksandar Mitrovic, Djordje Radak and Esma R. Isenovic
Affiliation:
Keywords: Metabolic syndrome, insulin resistance, cardiovascular disease.
Abstract: Metabolic syndrome (MetS) is a leading public health and clinical challenge worldwide. MetS represents a group of interrelated risk factors that predict cardiovascular diseases (CVD) and diabetes mellitus (DM). Its prevalence ranges between 10 and 84%, depending on the geographic region, urban or rural environment, individual demographic characteristics of the population studied (sex, age, racial and ethnic origin), as well as the criteria used to define MetS. Persons with MetS have higher mortality rate when compared with people without MetS, primarily caused by progressive atherosclerosis, accelerated by pro-inflammatory and pro-coagulation components of MetS. Considering the high prevalence of metabolic disorders (glucose metabolism disorder, hypertension, dyslipidaemia, obesity etc.), preventive healthcare should focus on changing lifestyle in order to reduce obesity and increase physical activity. This narrative review considers the available evidence from clinical and experimental studies dealing with MetS, and current treatment options for patients with insulin resistance and MetS.
Export Options
About this article
Cite this article as:
Gluvic Zoran, Zaric Bozidarka, Resanovic Ivana, Obradovic Milan, Mitrovic Aleksandar, Radak Djordje and Isenovic R. Esma, Link between Metabolic Syndrome and Insulin Resistance, Current Vascular Pharmacology 2017; 15 (1) . https://dx.doi.org/10.2174/1570161114666161007164510
DOI https://dx.doi.org/10.2174/1570161114666161007164510 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [Hot Topic: Nitric Oxide and Hydrogen Sulfide - Contribution of Gaseous Messengers to the Cardiovascular Control (Guest Editor: Sona Cacanyiova)]
Current Pharmaceutical Biotechnology The Etiology of Hypertension in the Metabolic Syndrome Part Three: The Regulation and Dysregulation of Blood Pressure
Current Vascular Pharmacology Neuroprotective Methodologies of Co-Enzyme Q10 Mediated Brain Hemorrhagic Treatment: Clinical and Pre-Clinical Findings
CNS & Neurological Disorders - Drug Targets A Case of Topiramate-Induced Epistaxis
Current Drug Safety Epidermal Growth Factor Receptor-Targeted Therapy of Colorectal Cancer with Panitumumab
Current Cancer Therapy Reviews Biogenic Peptides and Their Potential Use
Current Pharmaceutical Design FGF21 and its Relationship with Inflammatory and Metabolic Parameters in HIV Patients after Antiretroviral Treatment
Current HIV Research Factors Influencing Outcome of Patients Receiving Extracorporeal Membrane Oxygenation for Neonatal and Pediatric Respiratory Failure
Current Respiratory Medicine Reviews Hypertension in Chronic Kidney Disease: Novel Insights
Current Hypertension Reviews Breaking the Barrier of Cancer Through Liposome Loaded with Phytochemicals
Current Drug Delivery Editorial: Preeclampsia-Eclampsia, Time to Act and Time to Deepen Research
Current Women`s Health Reviews Vascular Protective Effects of Diabetes Medications that Mimic or Increase Glucagon-Like Peptide-1 Activity
Recent Patents on Cardiovascular Drug Discovery Supramolecular Chiro-Biomedical Aspect of β-Blockers in Drug Development
Current Drug Targets Nicotinamide Supplementation Protects Gestational Diabetic Rats by Reducing Oxidative Stress and Enhancing Immune Responses
Current Medicinal Chemistry A Multidisciplinary Atrial Fibrillation Clinic
Current Cardiology Reviews Red Wine Consumption and Prevention of Atherosclerosis: An In Vitro Model Using Human Peripheral Blood Mononuclear Cells
Current Pharmaceutical Design Arterial Stiffness in Haemodialyzed Patients: Findings and Controversies
Current Hypertension Reviews Role of Matrix Metalloproteinases in Animal Models of Ischemic Stroke
Current Vascular Pharmacology Nanoceuticals as an Emerging Field: Current Status and Future Prospective
Current Nutrition & Food Science Prognostic Value of Copeptin in Chronic Kidney Disease: From General Population to End-Stage Renal Disease
Current Protein & Peptide Science